By George Ongkojoyo 
The medical community has reached a significant milestone in maternal health safety following the publication of the most extensive systematic review to date regarding the use of acetaminophen during pregnancy. Researchers at City St George’s, University of London, have concluded that taking acetaminophen—widely known by the brand name Tylenol and the generic name paracetamol—does not increase the risk of autism, attention-deficit hyperactivity disorder (ADHD), or intellectual disabilities in children. Published on January 16, 2025, in The Lancet Obstetrics, Gynaecology & Women’s Health, the study serves as a robust rebuttal to years of mounting public anxiety and conflicting observational data that had previously suggested a potential link between the common pain reliever and neurodevelopmental challenges.
This comprehensive analysis arrives at a critical juncture for public health. For decades, acetaminophen has been the primary recommendation for pregnant individuals suffering from pain or fever, as alternative non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen are generally avoided due to known risks to fetal kidney and heart development. The new findings provide a high level of reassurance to both expectant parents and healthcare providers, reinforcing long-standing clinical guidelines that had been questioned by a series of smaller, less controlled studies over the last decade.
The Evolution of the Acetaminophen Controversy
The debate over the safety of acetaminophen during pregnancy intensified significantly in the early 2020s. While the drug has been used safely since the 1950s, a 2021 "consensus statement" published by a group of international scientists urged caution, citing a variety of observational studies that suggested a correlation between prenatal exposure and behavioral issues in children. This sparked a wave of media coverage and prompted several high-profile legal challenges against manufacturers, alleging that they failed to warn consumers of neurodevelopmental risks.
However, many experts in epidemiology and obstetrics remained skeptical of those earlier findings. The primary criticism was that these studies often suffered from "confounding by indication." This occurs when the reason for taking the medication—such as a high fever, a severe infection, or chronic maternal stress—is actually the factor influencing the child’s development, rather than the medication itself. Furthermore, these studies rarely accounted for the genetic predispositions of the parents, which play a dominant role in the manifestation of autism and ADHD.
By late 2024 and early 2025, the need for a definitive, high-quality meta-analysis became urgent. The research team at City St George’s sought to fill this gap by applying more rigorous filters to the existing body of evidence, specifically prioritizing studies that could isolate the effects of the drug from the effects of genetics and the home environment.
Methodology: The Power of Sibling Comparison
The core strength of this new review lies in its focus on sibling comparison studies. Traditional observational studies compare children from different families—one whose mother took acetaminophen and one whose mother did not. This approach is inherently flawed because the two families likely differ in myriad ways, including genetic background, socioeconomic status, and environmental exposures.
In contrast, sibling comparison studies look at two or more children born to the same mother. If a mother used acetaminophen during her first pregnancy but not her second, researchers can compare the outcomes of the two siblings. Because these children share approximately 50% of their DNA and are typically raised in the same household environment, this method effectively "controls" for many of the variables that plague other types of research.
The City St George’s team analyzed data from 43 previously published studies, but the weight of their conclusion rested heavily on the massive datasets involving siblings. The scope of the data was unprecedented:
- Autism Spectrum Disorder (ASD): Outcomes were assessed for 262,852 children.
- ADHD: Outcomes were assessed for 335,255 children.
- Intellectual Disability: Outcomes were assessed for 406,681 children.
When comparing siblings, the statistical "link" between acetaminophen and these conditions vanished. The researchers found that once genetic and environmental factors were accounted for, there was no measurable increase in risk associated with the medication.
Evaluating Study Quality and Bias
To ensure the integrity of their findings, the research team utilized the Quality In Prognosis Studies (QUIPS) tool. This framework allows scientists to objectively grade the "risk of bias" in each study based on factors like how participants were recruited, how medication use was measured, and how outcomes were diagnosed.
The analysis revealed a clear trend: the higher the quality of the study, the less likely it was to find a link between acetaminophen and neurodevelopmental issues. Even when the researchers restricted their meta-analysis only to the "low-risk" studies—those with the most rigorous designs and longest follow-up periods—the results remained consistent. Children followed for more than five years showed no long-term detrimental effects from prenatal exposure to the drug.
Professor Asma Khalil, the lead author of the study and a Consultant Obstetrician at City St George’s, emphasized that the earlier "alarms" were likely the result of misinterpreting data. "Our findings suggest that previously reported links are likely to be explained by genetic predisposition or other maternal factors such as fever or underlying pain, rather than a direct effect of the paracetamol itself," Khalil stated.
The Danger of Untreated Maternal Fever
One of the most significant implications of this study involves the risks of not taking acetaminophen when medically necessary. Fever during pregnancy is a known risk factor for various complications, including neural tube defects and other developmental anomalies. If pregnant individuals avoid acetaminophen out of fear, they may leave high fevers untreated, inadvertently placing the fetus at greater risk.
"The message is clear—paracetamol remains a safe option during pregnancy when taken as guided," Khalil noted. "This is important as paracetamol is the first-line medication we recommend for pregnant women in pain or with a fever, and so they should feel reassured."
Clinical guidelines from the American College of Obstetricians and Gynecologists (ACOG) and the Royal College of Obstetricians and Gynaecologists (RCOG) have consistently maintained that acetaminophen is the safest pain reliever available for pregnant patients. This new review provides the empirical evidence needed to bolster these recommendations in the face of public skepticism.
Chronology of Recent Findings and Public Response
The timeline leading to this publication reflects a period of intense scientific scrutiny:
- 2021: A "Consensus Statement" in Nature Reviews Endocrinology calls for more research and cautious use of acetaminophen, leading to widespread public concern.
- 2022-2023: Several large-scale European and North American cohort studies begin focusing on sibling comparisons, with preliminary data suggesting no link to ADHD or autism.
- Late 2024: Renewed public interest and ongoing litigation in the United States prompt researchers to synthesize all available high-quality data into a single meta-analysis.
- January 16, 2025: The Lancet Obstetrics, Gynaecology & Women’s Health publishes the City St George’s review, concluding no increased risk across all major neurodevelopmental categories.
The reaction from the medical community has been one of cautious relief. While no single study can ever claim to be the "final word" in science, the sheer volume of the data and the use of sibling controls make this the most definitive statement on the subject to date.
Identifying Remaining Gaps in Research
Despite the reassuring nature of the findings, the researchers acknowledged that certain questions remain unanswered due to limitations in the primary data. Because many of the 43 studies did not record specific details with high precision, the meta-analysis could not definitively determine if risks vary based on:
- Trimester of Exposure: Is the drug safer in the third trimester than the first?
- Dosage and Frequency: Does chronic, daily use carry more risk than a single dose?
- Fetal Sex: Are male or female fetuses more sensitive to the drug’s mechanisms?
The authors noted that while the overall risk appears non-existent, future research should aim to collect more granular data on these specific variables. However, they stressed that for the vast majority of pregnant individuals taking the medication occasionally for a headache or a fever, the current evidence is overwhelmingly positive.
Implications for Public Health and Clinical Practice
The publication of this study is expected to influence clinical practice and public health communication globally. For doctors, it provides a powerful tool to counsel patients who may be hesitant to treat a fever or manage pain during pregnancy. For the public, it serves as a reminder of the complexity of medical research and the danger of drawing conclusions from observational studies that do not account for genetics.
From a legal and regulatory perspective, this review may also impact ongoing litigation. By demonstrating that the purported link between acetaminophen and autism is likely a result of confounding factors rather than the drug itself, the study weakens the scientific basis for claims that manufacturers failed to warn of a known danger.
In the broader context of maternal-fetal medicine, this research underscores the importance of the "biopsychosocial" model of development. Autism and ADHD are complex, polygenic conditions influenced by a combination of thousands of genetic variants and various environmental factors. Attributing these conditions to a single over-the-counter medication was, in retrospect, a simplification that the current data does not support.
As healthcare systems move forward, the focus will likely return to the responsible use of all medications. The "as-needed" and "lowest effective dose" principles remain the gold standard for any pharmacological intervention during pregnancy. However, thanks to the rigorous work of the team at City St George’s, pregnant patients can once again view acetaminophen as a safe and reliable tool for maintaining their health and the health of their developing children.
